- Research article
- Open Access
18 F-Fluoride positron emission tomography/computed tomography for noninvasive in vivo quantification of pathophysiological bone metabolism in experimental murine arthritis
Arthritis Research & Therapyvolume 16, Article number: R155 (2014)
Evaluation of disease severity in experimental models of rheumatoid arthritis is inevitably associated with assessment of structural bone damage. A noninvasive imaging technology allowing objective quantification of pathophysiological alterations of bone structure in rodents could substantially extend the methods used to date in preclinical arthritis research for staging of autoimmune disease severity or efficacy of therapeutical intervention. Sodium 18 F-fluoride (18 F-NaF) is a bone-seeking tracer well-suited for molecular imaging. Therefore, we systematically examined the use of 18 F-NaF positron emission tomography/computed tomography (PET/CT) in mice with glucose-6-phosphate isomerase (G6PI)–induced arthritis for quantification of pathological bone metabolism.
F-fluoride was injected into mice before disease onset and at various time points of progressing experimental arthritis. Radioisotope accumulation in joints in the fore- and hindpaws was analyzed by PET measurements. For validation of bone metabolism quantified by 18 F-fluoride PET, bone surface parameters of high-resolution μCT measurements were used.
Before clinical arthritis onset, no distinct accumulation of 18 F-fluoride was detectable in the fore- and hindlimbs of mice immunized with G6PI. In the course of experimental autoimmune disease, 18 F-fluoride bone uptake was increased at sites of enhanced bone metabolism caused by pathophysiological processes of autoimmune disease. Moreover, 18 F-fluoride signaling at different stages of G6PI-induced arthritis was significantly correlated with the degree of bone destruction. CT enabled identification of exact localization of 18 F-fluoride signaling in bone and soft tissue.
The results of this study suggest that small-animal PET/CT using 18 F-fluoride as a tracer is a feasible method for quantitative assessment of pathophysiological bone metabolism in experimental arthritis. Furthermore, the possibility to perform repeated noninvasive measurements in vivo allows longitudinal study of therapeutical intervention monitoring.
Rheumatoid arthritis (RA) is one of the most common autoimmune diseases, affecting approximately 1% of the population in Europe and North America. Bone erosion can be detected as early as several weeks after the onset of the first clinical signs and symptoms of RA. Pathogenesis in preclinical models is similar to that in clinical RA; it is characterized by inflammation and bone destruction. In the past few decades, histopathological evaluation of joint sections has mainly been used for assessment of inflammation and bone destruction in small-rodent models of arthritis. Recently, we showed the benefit of state-of-the-art imaging modalities for visualization and quantitative assessment of inflammation in glucose-6-phosphate isomerase (G6PI)–induced arthritis using 2-deoxy-2-18 F-fluoroglucose (18 F-FDG) positron emission tomography/computed tomography (PET/CT). Also, it has been shown that cell proliferation can be detected in experimental arthritis with the PET proliferation tracer 3′-deoxy-3′-18 F-fluorothymidine.
18 F-fluoride not only can be used to label glucose and other molecules of physiologic relevance but also has favorable properties in the form of sodium 18 F-fluoride (18 F-NaF) as a radiotracer per se in noninvasive in vivo imaging to investigate musculoskeletal diseases. The use of 18 F-NaF as a bone imaging probe was established by Blau et al. in the early 1960s, but it was subsequently replaced by 99mTc-labeled tracers due to their availability, lower costs and the lower energy of 140-keV photons, allowing the use of γ-cameras. 18 F-fluoride PET is an increasingly used molecular imaging modality, not only in human skeletal disorders but also in small-animal preclinical research[6–8]. This is facilitated by the distribution and use of three-dimensional PET scanners with high spatial resolution in clinical medicine and advantages over 99mTc-labeled bone agents used for skeletal scintigraphy, such as higher diagnostic accuracy and reduced scanning time. Compared to γ-cameras, molecular imaging using PET provides the advantages of higher spatial resolution, higher sensitivity and three-dimensional tomographic image reconstruction. Furthermore, the combination of PET with μCT enables attenuation correction of radiotracer signaling, allowing quantitative measurements using 18 F-fluoride PET/CT.
Applied 18 F-NaF, dissociated into Na+ and 18 F−, is rapidly cleared from the blood and accumulates in the bone, where, on the hydroxyapatite surface, an OH− ion is replaced by an 18 F− ion to form fluorapatite. The incorporation of 18 F-fluoride in the bone is determined by vascular perfusion and bone surface accessible for ion exchange, indirectly reflecting bone formation and bone resorption. This means that 18 F-NaF can be used not only for the common measurement of bone mineral deposition but also for visualization of osteolytic increases of exposed bone surface, such as in the context of musculoskeletal autoimmune disease.
In clinical oncology, primary bone tumors and skeletal metastasis can reliably be detected by 18 F-fluoride PET[4, 11]. In mice, pathological osteoblastic activity can be detected even earlier by 18 F-fluoride PET/CT imaging than by radiography and corresponds to histological evaluation of increased bone formation. As with bone tumor pathogenesis, a pathologically increased bone metabolism is a central feature of chronic arthritis, resulting in functional disorders of the joints. Therefore, in our present study, we examined the use of 18 F-NaF small-animal PET/CT for the quantitative and noninvasive in vivo assessment of pathophysiological bone metabolism in acute and chronic stages of experimental G6PI-induced murine arthritis. 18 F-NaF PET quantification of bone destruction, visible as lesions in cortical bone surface and dysregulated bone formation, was validated using high-resolution CT measurements of the paws.
Glucose-6-phosphate isomerase–induced arthritis
DBA/1 mice were bred at the animal facility of the Jena University Hospital (Jena, Germany). All animal studies were approved by the local commission for animal protection (Thüringer Landesamt für Verbraucherschutz, Bad Langensalza, Germany; registered number 02-045/08). Arthritis was induced as described elsewhere. In brief, DBA/1 mice were immunized subcutaneously with 400 μg of recombinant human G6PI in emulsified complete Freund’s adjuvant (Sigma-Aldrich, Taufkirchen, Germany). Macroscopic evaluation of arthritis was performed according to severity of clinical manifestations in wrist and ankle joints, in metacarpophalangeal and metatarsophalangeal joints, and in digits and toes. Swelling and redness in wrist and ankle joints and in metacarpophalangeal and metatarsophalangeal joints, respectively, were graded from 0 to 3. A score of 0 indicates no macroscopically recognizable signs of arthritis, 1 indicates swelling and redness, 2 means strong swelling and redness and 3 indicates massive swelling and redness. Additionally, the number of digits and toes with inflamed joints were divided in half to avoid assessment imbalance because inflammation in the G6PI-induced arthritis model is located mainly in proximal joints of the paws. To calculate the total clinical score per animal, results from all paws were summed. For PET/CT measurements, mice were anesthetized with 1.5% to 2% isoflurane (Deltaselect, Dreieich, Germany) vaporized in oxygen (1.5 L/min) to prevent animal movement and reduce imaging artifacts. Respiration of mice under anesthesia was monitored. 18 F-fluoride (half-life = 109 minutes; Eckert & Ziegler, Bad Berka, Germany) with an activity of 10.4 ± 0.8 MBq was injected intravenously into the lateral tail vein. Longitudinal arthritis imaging was performed at various time points of acute and chronic clinical arthritis (n = 3 to 6 mice per time point). We obtained dynamic PET scans for kinetic analysis of tracer uptake in nonimmunized mice (n = 3).
Positron emission tomography/computed tomography in vivo imaging
In vivo18 F-NaF imaging was performed using a Siemens Inveon small-animal multimodality PET/CT system (Preclinical Solutions, Siemens Healthcare Molecular Imaging, Knoxville, TN, USA), characterized by the combination of two independently operating PET and CT scanners. Radial, tangential and axial resolutions at the center of the field of view of the PET module are 1.5 mm for this imaging modality[14, 15]. PET image acquisition was carried out with a coincidence timing window of 3.4 ns and an energy window of 350 to 650 keV. PET data acquisition was performed for 1,800 seconds, starting 50 minutes after tracer application. In kinetic analysis, PET data acquisition lasted 5,400 seconds and started concomitantly with radiotracer injection. Images were reconstructed into three-dimensional images using Fourier rebinning and three-dimensional ordered-subset expectation maximization algorithm. Attenuation of PET data was corrected based on the CT measurements. The CT module consists of a cone-beam X-ray μCT source (50-μm focal spot size) and a 3,072 × 2,048–pixel X-ray detector. In our μCT imaging protocol, we used an axial–transaxial resolution of 2,048 × 2,048–pixel, 80 kVp at 500 μA, 360° rotation and 360 projections per bed position for paw measurements and 3,072 × 2,048–pixel, 220° rotation and 120 projections per bed position for whole-animal attenuation scans, respectively. CT images were reconstructed using a Shepp-Logan filter and cone-beam–filtered back projection. To reduce stress due to overly prolonged measurement times, only high-resolution μCT data from hindpaws were acquired for correlation analysis of bone surface assessment with 18 F-fluoride PET and CT.
Assessment of pathophysiological bone metabolism with 18 F-fluoride or μCT
Quantitative analysis of 18 F-fluoride accumulation in the period from 50 to 80 minutes after 18 F-fluoride injection or 0 to 90 minutes, respectively, was enabled by image fusion technology in Siemens Inveon Research Workplace 4.0 software. For dynamic PET analysis, scans were started 5 seconds before radiotracer injection and continued for 90 minutes. The 90-minute data set was divided into 45 time frames (6 × 10 seconds, 6 × 20 seconds, 7 × 60 seconds, 10 × 120 seconds, 10 × 180 seconds and 6 × 300 seconds) during histogramming to construct time–activity curves. For static analysis, data from 75 to 80 minutes after 18 F-fluoride injection were analyzed in a single time frame. Radioisotope activity in the venous blood pool or in fore- or hindpaws, reflecting bone incorporation of 18 F-fluoride, was measured as standardized uptake value (SUV; g/ml) using PMOD 3.15 software (PMOD Technologies Ltd, Zurich, Switzerland) or Siemens Inveon Research Workplace 4.0 software. Guided by maximum intensity projection images, volumes of interest were drawn as spheres (ellipsoids) over anatomic structures of bones and joints. A threshold of 40% (max–min) was used to separate the site of tracer accumulation from background tissue signaling. Visualization of skeletal elements of the hindpaws was also done using PMOD 3.15 software.
Analyses of metatarsal CT data were performed using Definiens Developer XD™ 2.0.3 build 2015 software (Definiens, Munich, Germany). For segmentation of metatarsal bones, the automatic threshold routine was used. Then, individual bones were discriminated by watershed segmentation. Oversegmented fragments were merged manually to achieve three-dimensional objects of each bone. After identification of metatarsals 1 to 5, a local threshold was applied on each metatarsal bone to refine bone margins and remove remaining nonbone pixels. The threshold was calculated as the difference between mean pixel gray value and standard deviation of pixel gray values. Quantitative measurements of bone surface and bone volume were calculated for each metatarsal bone.
Statistical differences between groups were evaluated using the nonparametric Mann-Whitney U test. Correlation analyses (Spearman test) were performed for PET data and clinical scoring or PET and CT data, respectively, whereas CT surface data of all metatarsals, per paw, were summed. Statistical significance was accepted at P < 0.05 (*P < 0.05, **P < 0.01, ***P < 0.001). In bar charts and text, data are given as arithmetic means and standard errors of the mean (SEM). All calculations were performed using the software package IBM SPSS Statistics version 20.0 (IBM, Ehningen, Germany).
Inflammation and bone destruction in glucose-6-phosphate isomerase–induced arthritis
Immunization of animals with G6PI induced severe paw inflammation in DBA/1 mice (Figure 1A). Experimental disease was characterized by redness and swelling in wrist and ankle joints, as well as in dorsal areas of the paws and in metatarsophalangeal, metacarpophalangeal and phalangeal joints. Macroscopic scoring revealed onset of polyarthritis around 9 days after disease induction, maximum of inflammation at day 14 (d14) and a subsequent decrease until d33 (Figure 1B). Histopathology revealed bone erosion in skeletal elements of the inflamed paws (Figure 1C).
Kinetics of 18 F-fluoride bone uptake in mice
Radiotracer applied intravenously in the tail vein was immediately (0 to 10 seconds postinjection) transported to the heart via the blood flow (Figure 2A). Subsequent whole-body distribution of 18 F-fluoride resulted in thoracic and intestinal PET signaling (10 to 20 seconds postinjection). After 3 minutes, the pattern of 18 F-fluoride PET signaling indicated onset of bone accumulation, and signaling from the kidneys and bladder revealed partial radiotracer excretion. Twenty minutes after radiotracer injection, signaling of nonexcreted 18 F-fluoride was restricted mainly to bone and continued to increase until the end of measurement at 90 minutes.
Concomitantly, the quantitative time–activity curve analysis of 18 F-fluoride paw uptake revealed rapid radiotracer accumulation beginning immediately after injection and tracer signaling remaining at almost the same level from 40 to 90 minutes postinjection (Figure 2B). At 45 minutes postinjection, 90% of 18 F-fluoride uptake was achieved (SUVmean = 1.8), compared to bone radiotracer signaling after 90 minutes (SUVmean = 1.9). In contrast, blood pool tracer activity measured in the venae cavae region showed a rapid decline after an activity maximum (SUVmax = 15.2), within minutes following injection, reflecting rapid clearance of 18 F-fluoride from the blood.
Localization of exact sites of 18 F-fluoride paw bone uptake in glucose-6-phosphate isomerase–induced arthritis
Detailed three-dimensional anatomical μCT measurements allowed identification of metatarsal and phalangeal bones and joints, and PET imaging revealed radiotracer uptake in the paws during the course of experimental arthritis (Figure 3A). Low 18 F-fluoride accumulation before immunization switched to a distinct tracer uptake in the acute (d14) and chronic (d28) stages of disease and declined during late remitting arthritis (d50). Coregistration of PET and CT data enabled exact localization of 18 F-fluoride accumulation in arthritic mice.Detailed, three-dimensional anatomical information obtained by high-resolution μCT enabled visualization of the bone surfaces of phalangeal, metatarsal, tarsal and tibial bones. Compared to nonarthritic control animals (Figure 3B, left), pathologic bone metabolism in the mice with G6PI-induced arthritis induced a distinct increase in bone roughness (Figure 3B, right).
Quantification of pathophysiological bone metabolism using 18 F-fluoride PET in progressing murine arthritis
To analyze the usability of the 18 F-fluoride PET imaging modality for quantification of pathological bone metabolism in experimental arthritis models, we measured 18 F-fluoride uptake in all paws of mice with G6PI-induced arthritis at five different time points of disease. Before onset of clinical arthritis (that is, in bone tissue without pathological changes (d8), there were only low levels of 18 F-fluoride accumulation in wrist (Figure 4A) and ankle (Figure 4B) joints, measured as SUV. In acute clinical arthritis at d11, paw inflammation was associated with an increase in bone metabolism and induced a significant increase of 18 F-fluoride uptake compared to d8 (P = 0.019 (wrist) and P = 0.002 (ankle)). Mean SUVs at d8 were 2.08 ± 0.1 in carpal joints and 4.0 ± 0.2 in tarsal joints, and at d11 mean SUVs were 3.8 ± 0.6 in carpal joints and 5.8 ± 0.5 in tarsal joints. Mean 18 F-fluoride uptake was further significantly increased at d18 (4.4 ± 0.5 (carpal) and 6.3 ± 0.5 (tarsal)) and d25 (5.6 ± 0.6 (carpal) and 6.5 ± 0.6 (tarsal)), followed by a decrease at d39 (4.4 ± 0.5 (carpal) and 5.0 ± 0.4 (tarsal)). PET data revealed a 1.3- to 2.8-fold increase in 18 F-fluoride bone uptake in the paws at progressive stages of inflammatory arthritis, which always differed significantly from 18 F-fluoride accumulation before onset of clinical disease. This finding indicated a rise of pathological bone-degrading and bone-forming processes leading to joint dysfunction, characteristic for RA and its animal models.
To examine the general effects of arthritis on 18 F-fluoride uptake in elements of the skeleton, we quantified PET signaling in medial and distal femoral bones. SUVs revealed high tracer uptake (SUV > 10) in trabecular distal areas of the femur (Figure 4C). Except for late remitting arthritis (d39), SUVs remained at a similar level at different stages of G6PI-induced arthritis, indicating only a slight influence of pathological bone metabolism associated with arthritis on distal femoral tracer uptake. In contrast to trabecular distal areas, mean SUVs in median cortical areas of the femur ranged from 2.1 to 2.2 in all stages of arthritis (Figure 4D), additionally negating general effects of arthritis on bone accumulation of 18 F-fluoride at sites without clinical manifestations of disease. 18 F-fluoride PET/CT measurements in healthy mice without any pathological conditions revealed a nonequal pattern of bone tracer uptake (Additional file1: Figures S1A and S1B). There were hotspots of PET signaling in proximal joints of the pectoral girdle; in the pelvis, including the knees; and in spinal and cranial bones. Volume-rendering of the knee joints revealed a coincidence of increased 18 F-fluoride accumulation and trabecular bone (Additional file1: Figure S1C). Therefore, we assume that the increased surface in trabecular bones, meeting the demands of distinct mechanical stress or saving weight, is the cause for the observed heterogeneous pattern of 18 F-fluoride uptake in skeletal bone.
Quantification of pathophysiological bone metabolism using μCT
To validate assessment of pathophysiological bone metabolism by 18 F-fluoride PET imaging, bone parameters in μCT data were quantified. Bone surface showed no difference for metatarsals 1 to 5 between unimmunized mice and mice with acute inflammatory arthritis (Figure 5A, d14). In chronic and remitting arthritis (Figure 5A, d28, d35 and d50), bone surface was significantly increased due to bone lesions or dysfunctional bone formation. The course of bone surface assessment was consistent with the course of SUV data obtained by 18 F-fluoride PET. The volume of metatarsal bones revealed a slight increase at d35, followed by a subsequent decline to previous levels in late experimental arthritis at d50 (Figure 5B). Overall, bone volume was largely unaffected by arthritis pathogenesis.
Regression analysis of clinical parameters and quantitative PET and CT assessment of bone parameters
To validate quantification of pathological bone metabolism by 18 F-fluoride PET imaging in experimental arthritis, we performed correlation analysis of quantitative PET results with semiquantitative clinical scoring data and assessment of bone surface roughness destruction by μCT. Although inflammation and bone destruction are associated but functionally not necessarily constrained mechanisms of arthritis pathophysiology, macroscopic clinical scoring and SUV of 18 F-fluoride were significantly correlated (Figure 6A). More importantly, there was a significant correlation of quantitative assessment of pathological bone metabolism by 18 F-fluoride SUV and assessment of bone surface by μCT (Figure 6B), demonstrating the feasibility of these modalities for quantification of bone destruction in experimental arthritis. Therefore, small-animal 18 F-fluoride PET/CT is a reliable imaging method for in vivo quantification of arthritis-induced bone erosion and bone malformation, correlating with assessment of pathophysiologic bone surface alterations using μCT.
The usefulness of the small-animal PET/CT imaging modality using 18 F-NaF as a radiotracer is not restricted to the detection of primary bone tumors and skeletal metastasis in cancer research. 18 F-fluoride PET/CT imaging is also a valid technique for use in the assessment of disease severity according to pathological bone turnover in the field of preclinical arthritis research. In this study, in which we employed the G6PI-induced arthritis model, we focused on the feasibility of using 18 F-fluoride PET to visualize and quantify pathological bone metabolism in distal murine arthritic joints noninvasively and in vivo. In addition to joint inflammation, which can easily be quantified by 18 F-FDG PET/CT according to activation and proliferation of resident cells and migrated cells of the immune system, bone damage is the second major parameter used for assessment of arthritis severity.
In contrast to 18 F-FDG, which is trapped in cells at sites of inflammation due to pathologically increased glucose metabolism, 18 F-fluoride represents for specific radiotracer accumulation in the bone. Erosive processes degrading bone and cartilage and dysfunctional bone repair mechanisms in RA and its animal models are associated with an increased bone surface. Therefore, the increased mineral-binding capacity results in site-specific 18 F-fluoride uptake in arthritic joints, which can easily be used for visualization and, more importantly, provides a measurement method for the quantification of pathological bone metabolism in preclinical arthritis models. The results of our studies show increased uptake of 18 F-fluoride in the paws of arthritic mice and reveal that the 18 F-fluoride PET/CT quantification of pathologic bone metabolism in arthritis pathogenesis significantly correlated with our assessment of pathophysiologic bone surface alterations based on high-resolution μCT measurements.
Radioisotope imaging is, to date, one of the most applicable imaging modalities for functional and whole-body in vivo quantification of bone metabolism in mice. Compared to other radiopharmaceuticals used for bone imaging, such as 99mTc, 18 F-fluoride has some beneficial attributes. First, 18 F-fluoride has a high affinity to bone, resulting in favorable skeletal kinetics. Within 60 minutes after intravenous injection, only 10% of the injected dose is still located in the bloodstream. Thus the concurrence of rapid bone uptake and fast blood-pool clearance yields a favorable bone-to-background ratio. Additionally, 18 F-fluoride does not accumulate in inflamed soft tissue and only minimally binds to serum proteins. Furthermore, small-animal 18 F-NaF PET measurements have an excellent reproducibility in animal models of bone disease[6, 17].
One limiting factor in 18 F-fluoride PET imaging might be vascularization of the tissue restricting tracer delivery. In contrast to epithelial tissue, the circulation in well-vascularized bone tissue is less affected by exogenous factors, allowing reproducible data acquisition. In experimental arthritis, the increased vascularization and blood flow in inflamed tissue may influence tracer delivery and, therefore, PET signaling at stages of acute inflammation. Nevertheless, at time points of maximal tracer uptake in our experiments, clinical arthritis was already remitting and macroscopically visible signs of inflammation were diminished. Another important aspect of 18 F-fluoride PET imaging is bone structure. Skeletal elements consisting of cortical and trabecular bone result in strong baseline PET signaling. This is presumably caused by the manifold increase in bone surface and less by increased metabolism at these sites, as binding capacities of cortical and trabecular bone are only slightly different. However, both decrease significantly if bone matrix is demineralized. Therefore, if bones with cancellous and noncancellous structures are located near regions of interest, data analyses require a high degree of anatomical accuracy, which can be achieved with μCT. In quantification of experimental arthritis severity, we found that the effect of high baseline signaling in tibial and radial bones was of negligible relevance for 18 F-fluoride PET imaging, because signaling hotspots of arthritis pathogenesis were located in tarsal, metatarsal and carpal and metacarpal bones. Another source of a high and pathological 18 F-fluoride baseline PET signaling independent of autoimmune disease pathogenesis might be the preoccurrence of osteoarthritis resulting in mechanical bone erosion. Whereas this aspect is not relevant for imaging in experimental arthritis models, it should be considered in RA bone imaging, where age is a risk factor.
In our present study, we demonstrate the capability of 18 F-fluoride PET to monitor and quantify pathological bone conditions in the model of G6PI-induced arthritis. Furthermore, we validated this bone imaging technique successfully by using bone surface μCT data. Because 18 F-fluoride PET is a noninvasive and nondestructive way to measure bone metabolism in vivo, this molecular imaging modality is not only useful for numerous applications in basic animal science, where pathophysiological bone metabolism is of interest, but also is a valuable tool for use in preclinical arthritis research, where pathological bone destruction and inflammation are the major parameter used for assessment of disease severity.
- 18 F-FDG:
18 F-labelled fluorodeoxyglucose
Glucose-6-phosphate isomerase–induced arthritis
Positron emission tomography
Standardized uptake value.
Backhaus M, Kamradt T, Sandrock D, Loreck D, Fritz J, Wolf KJ, Raber H, Hamm B, Burmester GR, Bollow M: Arthritis of the finger joints: a comprehensive approach comparing conventional radiography, scintigraphy, ultrasound, and contrast-enhanced magnetic resonance imaging. Arthritis Rheum. 1999, 42: 1232-1245. 10.1002/1529-0131(199906)42:6<1232::AID-ANR21>3.0.CO;2-3.
Irmler IM, Opfermann T, Gebhardt P, Gajda M, Bräuer R, Saluz HP, Kamradt T: In vivo molecular imaging of experimental joint inflammation by combined 18 F-FDG positron emission tomography and computed tomography. Arthritis Res Ther. 2010, 12: R203-10.1186/ar3176.
Fuchs K, Kohlhofer U, Quintanilla-Martinez L, Lamparter D, Kötter I, Reischl G, Röcken M, Pichler BJ, Kneilling M: In vivo imaging of cell proliferation enables the detection of the extent of experimental rheumatoid arthritis by 3′-deoxy-3′-18 F-fluorothymidine and small-animal PET. J Nucl Med. 2013, 54: 151-158. 10.2967/jnumed.112.106740.
Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I: The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, 18 F-fluoride PET, and 18 F-fluoride PET/CT. J Nucl Med. 2006, 47: 287-297.
Blau M, Nagler W, Bender MA: Fluorine-18: a new isotope for bone scanning. J Nucl Med. 1962, 3: 332-334.
Berger F, Lee YP, Loening AM, Chatziioannou A, Freedland SJ, Leahy R, Lieberman JR, Belldegrun AS, Sawyers CL, Gambhir SS: Whole-body skeletal imaging in mice utilizing microPET: optimization of reproducibility and applications in animal models of bone disease. Eur J Nucl Med Mol Imaging. 2002, 29: 1225-1236.
Hsu WK, Virk MS, Feeley BT, Stout DB, Chatziioannou AF, Lieberman JR: Characterization of osteolytic, osteoblastic, and mixed lesions in a prostate cancer mouse model using 18 F-FDG and 18 F-fluoride PET/CT. J Nucl Med. 2008, 49: 414-421. 10.2967/jnumed.107.045666.
Grant FD, Fahey FH, Packard AB, Davis RT, Alavi A, Treves ST: Skeletal PET with 18 F-fluoride: applying new technology to an old tracer. J Nucl Med. 2008, 49: 68-78.
Tomlinson RE, Silva MJ, Shoghi KI: Quantification of skeletal blood flow and fluoride metabolism in rats using PET in a pre-clinical stress fracture model. Mol Imaging Biol. 2012, 14: 348-354. 10.1007/s11307-011-0505-3.
Blau M, Ganatra R, Bender MA: 18 F-fluoride for bone imaging. Semin Nucl Med. 1972, 2: 31-37. 10.1016/S0001-2998(72)80005-9.
Langsteger W, Heinisch M, Fogelman I: The role of fluorodeoxyglucose, 18 F-dihydroxyphenylalanine, 18 F-choline, and 18 F-fluoride in bone imaging with emphasis on prostate and breast. Semin Nucl Med. 2006, 36: 73-92. 10.1053/j.semnuclmed.2005.09.002.
Schett G, Gravallese E: Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment. Nat Rev Rheumatol. 2012, 8: 656-664. 10.1038/nrrheum.2012.153.
Schubert D, Maier B, Morawietz L, Krenn V, Kamradt T: Immunization with glucose-6-phosphate isomerase induces T cell-dependent peripheral polyarthritis in genetically unaltered mice. J Immunol. 2004, 172: 4503-4509. 10.4049/jimmunol.172.7.4503.
Constantinescu CC, Mukherjee J: Performance evaluation of an Inveon PET preclinical scanner. Phys Med Biol. 2009, 54: 2885-2899. 10.1088/0031-9155/54/9/020.
Visser EP, Disselhorst JA, Brom M, Laverman P, Gotthardt M, Oyen WJ, Boerman OC: Spatial resolution and sensitivity of the Inveon small-animal PET scanner. J Nucl Med. 2009, 50: 139-147.
Blake GM, Park-Holohan SJ, Cook GJ, Fogelman I: Quantitative studies of bone with the use of 18 F-fluoride and 99mTc-methylene diphosphonate. Semin Nucl Med. 2001, 31: 28-49. 10.1053/snuc.2001.18742.
Frost ML, Blake GM, Park-Holohan SJ, Cook GJ, Curran KM, Marsden PK, Fogelman I: Long-term precision of 18 F-fluoride PET skeletal kinetic studies in the assessment of bone metabolism. J Nucl Med. 2008, 49: 700-707. 10.2967/jnumed.107.046987.
Mitterhauser M, Toegel S, Wadsak W, Mien LK, Eidherr H, Kletter K, Viernstein H, Kluger R, Engel A, Dudczak R: Binding studies of [18 F]-fluoride and polyphosphonates radiolabelled with [99mTc], [111In], [153Sm] and [188Re] on bone compartments: verification of the pre vivo model?. Bone. 2005, 37: 404-412. 10.1016/j.bone.2005.04.027.
The authors express their gratitude to Alexander Heidrich, Cornelia Huettich and Annett Krause for excellent technical and organizational assistance and to the Bundesministerium für Bildung und Forschung for financial support (BMBF; FKZ 0316040B).
The authors declare that they have no competing interests.
II was responsible for study conception and design, animal experiments and data collection, PET data analysis and interpretation and manuscript writing. PG was responsible for study design, animal experiments and data collection, PET data analysis and manuscript writing. TO was responsible for animal experiments and data collection and PET data analysis. BH and MF were responsible for μCT data analysis and interpretation. HS and TK were responsible for data interpretation and critical revision of manuscript. All authors read and approved the final version of the manuscript.